miR-31 regulates energy metabolism and is suppressed in T cells from patients with Sjögren's syndrome.
Alina JohanssonWilliam A NybergMaria SjöstrandNoah MoruzziPetra BergmanMohsen KhademiMagnus AnderssonFredrik PiehlPer-Olof BerggrenRuxandra CovacuMaja JagodicAlexander EspinosaPublished in: European journal of immunology (2018)
Systemic autoimmune diseases are characterized by the overexpression of type I IFN stimulated genes, and accumulating evidence indicate a role for type I IFNs in these diseases. However, the underlying mechanisms for this are still poorly understood. To explore the role of type I IFN regulated miRNAs in systemic autoimmune disease, we characterized cellular expression of miRNAs during both acute and chronic type I IFN responses. We identified a T cell-specific reduction of miR-31-5p levels, both after intramuscular injection of IFNβ and in patients with Sjögren's syndrome (SjS). To interrogate the role of miR-31-51p in T cells we transfected human CD4+ T cells with a miR-31-5p inhibitor and performed metabolic measurements. This identified an increase in basal levels of glucose metabolism after inhibition of miR-31-5p. Furthermore, treatment with IFN-α also increased the basal levels of human CD4+ T-cell metabolism. In all, our results suggest that reduced levels of miR-31-5p in T cells of SjS patients support autoimmune T-cell responses during chronic type I IFN exposure.
Keyphrases
- dendritic cells
- immune response
- endothelial cells
- drug induced
- cell proliferation
- end stage renal disease
- multiple sclerosis
- ejection fraction
- chronic kidney disease
- newly diagnosed
- transcription factor
- poor prognosis
- long non coding rna
- case report
- liver failure
- prognostic factors
- rheumatoid arthritis
- genome wide
- induced pluripotent stem cells
- dna methylation
- disease activity
- patient reported outcomes
- long noncoding rna
- ultrasound guided
- respiratory failure
- patient reported
- hepatitis b virus
- mechanical ventilation